Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term givinostat in JAK2V617F-positive chronic myeloproliferative neoplasms
2024-512413-40-00Phase 2Authorised
- Sponsor
- Italfarmaco
- Start
- Jun 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of givinostat in myeloproliferative disorder (MPD), polycythemia vera (PV), thrombocythemia and 1 more, sponsored by Italfarmaco. Primary endpoints: Long-term safety and tolerability, Long-term efficacy in PV and ET and 1 more. Planned start Jun 2024; status: authorised.
02
Drugs
givinostat
03
Conditions
myeloproliferative disorder (MPD)polycythemia vera (PV)thrombocythemiamyelofibrosis (MF)
Beyond the preview
Go deeper on 2024-512413-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512413-40-00.